BDRX · Biodexa Pharmaceuticals Plc
$1.54
+0.07 (+4.76%)
At close · Aug 7
Market Cap
$1.33M
Shares
904,066
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.54
Open$1.49
Day$1.40–1.68
52W$1.02–59.40
Avg vol 30d325K
Short int10K · 1.1% float · 1.0d
Short vol69%
Last earningsJun 30, 2021
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−84%
below
Price vs 50-day avg
−38%
below
RSI (14)
34
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−38%
trailing
6-month return
−71%
trailing
YTD return
−86%
this year
Relative strength
−85%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $10 — 200d above 50d
Institutional flow
Distributing
5 of 8 funds reported for Jun 30 · net -2.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.10% of float · ▼ -85.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Squeeze score
31
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
174%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
15.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−84%
Bearish
Price vs 50-day avg
−38%
Bearish
RSI (14)
34
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $10 — 200d above 50d
Institutional flow
Distributing
5 of 8 funds reported for Jun 30 · net -2.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.10% of float · ▼ -85.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 1%
52-wk high $59
vs 200-day avg -84%
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDRX
this stock
Biodexa Pharmaceuticals Plc
|
$1.33M | -86.4% | — | — | 1.1% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +14.6% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.68B | +9.4% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.49B | +1.9% | +20.8% | 19.1 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +2.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
8
- % held
- 7.9%
- Reported
- 5 of 8
- Top holder
- SABBY MANAGEMENT, LLC
Held
Float
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDRX | +16.7% | -38.2% | -71.5% | +16.7% | -86.4% |
| SPY | +3.5% | +2.4% | +13.4% | +3.5% | +13.4% |
| vs SPY | +13.2% | -40.6% | -84.9% | +13.2% | -99.8% |